ArticleCommunications biology2021
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer.Human vaccines & immunotherapeutics · 2026Article
- Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor.Experimental hematology & oncology · 2026Article
- Regulatory T cells in cancer anti-PD-(L)1 therapy.Human cell · 2025Review
- Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade.Journal for immunotherapy of cancer · 2025Article
- Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy.Journal of nanobiotechnology · 2025Article
- Article
- Review
- Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.Frontiers in immunology · 2024Article
- Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice.Journal for immunotherapy of cancer · 2023Article
- Inducible nitric oxide synthase (iNOS)-activated Cxcr2 signaling in myeloid cells promotes TGFβ-dependent squamous cell carcinoma lung metastasis.Cancer letters · 2023Article
- Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.Journal of cellular and molecular medicine · 2023Review
- Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial.EBioMedicine · 2022Review
- Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.Molecular oncology · 2022Review
- Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies.Molecular carcinogenesis · 2022Article
- Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.Frontiers in oncology · 2022Review
- Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Alexander A StraitDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-2397-8311
Rachel A WoolaverDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Spencer C HallDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-6783-2344
Christian D YoungDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Sana D KaramDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Antonio JimenoDepartment of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Yan LanEMD Serono Research and Development Institute Inc., Billerica, MA, USA.
David RabenDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Jing H WangDepartment of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. jhw51@pitt.edu.ORCID 0000-0003-4343-2527
Xiao-Jing WangDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. xj.wang@cuanschutz.edu.ORCID 0000-0001-8695-7361
University of Colorado Anschutz Medical Campus · USMerck (Germany) · DEUPMC Hillman Cancer Center · USVA Eastern Colorado Health Care System · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MPREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM007635 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 1985 to 2023
$6.1MTraining in Translational Research of Skin DiseasesT32AR007411 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA, ROOP, DENNIS · 1986 to 2025
$4.8MTraining in Translational Research of Lung, Head and Neck CancerT32CA174648 · NCI · UNIVERSITY OF COLORADO DENVER · PI KARAM, SANA D · 2013 to 2022
$4.2MElucidating Mechanism of Immune Evasion in Head and Neck CancersR01DE027329 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JING HONG, WANG, XIAO-JING · 2018 to 2022
$2.8MMechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCCR01DE028420 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI WANG, JING HONG, WANG, XIAO-JING · 2019 to 2023
$2.7MIdentifying oral cancer stem cell properties affected by the microenvironmentR01DE024371 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO, WANG, XIAO-JING · 2014 to 2017
$2.1MMechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancersF31DE027854 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI WOOLAVER, RACHEL A · 2018 to 2020
$100kMechanisms of Breaking Indolence in Squamous Cell CarcinomaI01BX003232 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI WANG, XIAO-JING · 2017 to 2025
–BLRD VA I01 BX003232NCI NIH HHS P30 CA046934NCI NIH HHS T32 CA174648NIAMS NIH HHS T32 AR007411NIDCR NIH HHS F31 DE027854NIDCR NIH HHS R01 DE024371NIDCR NIH HHS R01 DE027329NIDCR NIH HHS R01 DE028420NIGMS NIH HHS T32 GM007635
Abstract
Transforming growth factor beta (TGFβ) and programmed death-ligand 1 (PD-L1) are often overproduced in refractory squamous cell carcinoma (SCC). We examined spatial patterns of PD-L1
Indexed as
AnimalsB7-H1 AntigenCarcinoma, Squamous CellFemaleMiceMice, Inbred C57BLTransforming Growth Factor betaTumor MicroenvironmentB7-H1 AntigenCd274 protein, mouseTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.